← All companies
$285.75
+0.79% (+$2.23) on the day
Close Nov 13, 2026
Market cap
$689B
1 month
+12.82%
52-week range
$193.45–$286.08
Last month
Why we cover it
Sells Spravato, the esketamine nasal spray approved in 2019 for treatment-resistant depression and today's main branded option for it. Its venture arm co-led Delix Therapeutics' $100 million round in November 2026 for a psychedelic-inspired depression drug without hallucinations.
Financials
| Cash & equivalents | $16.9B | as of Sep 27, 2026 · 10-Q |
| Revenue | $25.4B | quarter ended Sep 27, 2026 · 10-Q |
| Research & development | $4.65B | quarter ended Sep 27, 2026 · 10-Q |
| Net income (loss) | $210M | quarter ended Sep 27, 2026 · 10-Q |
From the company's SEC filings. See all filings ↗
Patents Patent tracker
| Holder | Compounds | Granted | Pending | Expire |
|---|---|---|---|---|
| Janssen Pharmaceutica N.V. | Ketamine | 2 | 11 | 2038 |
News (8)
- Nov 12, 2026 Johnson & Johnson Co-Leads a $100M Bet on a Psychedelic-Inspired Depression Drug Without the Trip
- Oct 30, 2026 FDA Approves NRx's Generic Ketamine, But Its Bid to Ban Rivals' Products Is Still Pending
- Oct 28, 2026 Eli Lilly's Carole Ho Says 5-MeO-DMT "Fits the Spravato Model" as Investors Call Pharma "Cash Rich and Pipeline Poor"
- Oct 23, 2026 Norway Pays for Ketamine Therapy Nationally. A UK Trial Just Beat Standard NHS Talk Therapy 89% to 45%.
- Oct 20, 2026 A BBC Documentary Followed Teenage Ketamine Addicts Into a Bladder Ward. The Times Gave It Four Stars.
- Oct 6, 2026 The Same Thing That Makes Ketamine a Breakthrough Antidepressant Makes It Dangerous Without Consent
- Aug 28, 2026 New on Altitude: Ketamine Has More Patents Than Any Compound We Track — So Why Isn't Big Pharma More Interested?
- Aug 20, 2026 Why Some Depression Doesn't Respond to Antidepressants — and What Doctors Try Next
In the Journal (9)
- Nov 12, 2026 How Long Does Relief Last? Antidepressants vs. Psychedelics, by the Numbers
- Nov 7, 2026 After the Election, the Fights Move Indoors: ICER, a Courtroom and a New Drug Law for Psilocybin
- Oct 20, 2026 Altitude People Series, Week 1 — Sports: The Athletes Who Went Public About Psychedelics, and Why
- Sep 11, 2026 The Psychedelic Money Rankings: $11 Billion Public, $1.6 Billion Private, $140 Million From Governments
- Aug 28, 2026 Ketamine Has More Patents Than Any Compound We Track. So Why Isn't Big Pharma More Interested?
- Aug 28, 2026 Altitude Intelligence Brief: Who's Actually Making Money on Depression, Anxiety, and PTSD
- Aug 26, 2026 Psychedelics in Uniform: What the Military Did to Soldiers, and What the VA Is Now Asking of Veterans
- Aug 20, 2026 Psilocybin Has 223 Patents in Play. Here's Who Actually Holds Them.
- Jul 29, 2026 Eli Lilly Just Paid $3.8 Billion for the Same Molecule People Get From a Toad
Prices are end-of-day closes from Nasdaq; financials come from SEC filings. Not investment advice.